IWA
REGN icon

Icon Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Icon Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$864K Sell
1,259
-65
-5% -$49.8K 0.06% 187
2025
Q4 		$1.02M Buy
1,324
+182
+16% +$124K 0.07% 173
2025
Q3 		$642K Buy
1,142
+387
+51% +$219K 0.04% 233
2025
Q2 		$396K Buy
755
+170
+29% +$94.9K 0.03% 278
2025
Q1 		$371K Buy
585
+180
+44% +$124K 0.03% 258
2024
Q4 		$288K Sell
405
-9
-2% -$7.55K 0.02% 305
2024
Q3 		$435K Buy
414
+2
+0.5% +$2.23K 0.04% 228
2024
Q2 		$445K Sell
412
-116
-22% -$112K 0.04% 224
2024
Q1 		$508K Buy
528
+35
+7% +$33.3K 0.05% 208
2023
Q4 		$433K Buy
+493
New +$406K 0.05% 212
2022
Q4 		$247K Sell
342
-43
-11% -$31.7K 0.03% 281
2022
Q3 		$265K Buy
+385
New +$242K 0.03% 260

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Icon Wealth Advisors's REGN Position: Q1 2026 in Review

Icon Wealth Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 4.9% in Q1 2026, selling an estimated $49.8K and leaving 1,259 shares worth $864K. The position accounts for 0.06% of the portfolio, ranked #187.

Icon Wealth Advisors first reported a position in REGN in Q3 2022 and has held it in 12 quarters since. The position peaked at $1.02M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Icon Wealth Advisors held 1,259 shares of Regeneron Pharmaceuticals worth $864K as of Q1 2026.
  • Icon Wealth Advisors sold 65 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $49.8K.
  • Regeneron Pharmaceuticals made up 0.06% of Icon Wealth Advisors's portfolio in Q1 2026, its #187 holding.
  • Icon Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
  • Icon Wealth Advisors's Regeneron Pharmaceuticals position peaked at $1.02M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Icon Wealth Advisors's 13F filing for Q1 2026, filed 12 May 2026.